Dobutamine is chosen over dopamine in cardiogenic shock without significant hypotension because dobutamine:

• A Acts primarily on dopaminergic (DA1) receptors to increase renal blood flow
• B Releases endogenous norepinephrine from sympathetic terminals, raising systemic vascular resistance
• C Blocks cardiac β2 receptors while stimulating β1, thus preventing arrhythmias
• D Is a selective β1 agonist with minimal α1 and β2 agonism, increasing cardiac contractility without marked vasoconstriction ✓

Explanation

Dobutamine is a synthetic catecholamine with preferential β1 agonism (with mild β2 and minimal α1 activity), increasing myocardial contractility and cardiac output without substantial vasoconstriction. In cardiogenic shock without hypotension, the goal is to improve pump function rather than increase afterload; dopamine at moderate doses causes norepinephrine release and vasoconstriction, worsening afterload. Dobutamine does not rely on indirect catecholamine release or DA1 receptor activation.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.